KKR launches Allyntra, a precision-engineered medtech platform

KKR (NYSE: KKR) has launched Allyntra, a newly formed precision-engineered solutions platform focused on medical technology and other precision end markets, according to a press release from the company.

The platform builds on KKR's existing investment in Precipart, made through its Health Care Strategic Growth Fund II, with Precipart serving as a foundational business within the new entity. KKR said it is committing additional capital to support Allyntra's growth through acquisitions and continued investment.

Robbie Atkinson has been appointed Chief Executive Officer of Allyntra and Brian Highley as Chairman. Atkinson previously served as CEO and President of Medical Manufacturing Technologies, where he led the company through a period of expansion that culminated in its sale to Perimeter Solutions (NYSE: PRM). Highley brings more than 30 years of experience in the medical technology industry and previously served as CEO of Cirtec.

Oliver Laubscher, who served as CEO of Precipart, will transition to join the Allyntra Board of Directors. The Laubscher family will remain a shareholder in the platform.

"Since first investing in Precipart in 2023, we've become increasingly convinced of the opportunity to create a distinctive precision-engineered solutions platform," said Ali Satvat, Global Head of Health Care Strategic Growth and Co-Head of Americas Private Equity Health Care at KKR, and Anuv Ratan, Managing Director at KKR.

Allyntra focuses on the design, development, and manufacture of engineered components and assemblies for surgical applications, including robotic-assisted surgery and minimally invasive surgery.

You May Also Be Interested In

• Apple suing OpenAI over alleged misappropriation of trade secrets
• Mary Junck to retire from Lee Enterprises board in July
• Enova adds Maria Veltre to board as two directors retire